Through this platform, we facilitate the discovery, and optimization and pre-clinical evaluation of drug candidates, as well as the advancement of clinical development for investigational drugs.
Leveraging our insights into inflammatory responses and immune regulation, our innovative drug pipeline is focused on investigational therapies for indications with significant unmet medical needs and substantial global market potential. The pipeline includes one potential first-in-class oncology drug candidate and three additional preclinical-stage innovative candidates for the treatment of oncology, ophthalmology and respiratory diseases.
Fujian Haixi New Pharmaceutical Creation Co., Ltd. Fujian ICP Record No. 12015727 Internet Drug Information Service Qualification Certificate No.: (Min) - Non-operating-2023-0063
Some of the text and pictures on this site are from the Internet and are only used for sharing and learning. If your rights and interests are infringed, please inform us in time, and this site will deal with or replace them in time.
